Vivek Bhalla, MD, FASN, FAHA

@bhallaresearch.bsky.social

Exploring Molecular Mechanisms of Kidney Disease and Hypertension; Associate Professor, Stanford Medicine; Director, Stanford Hypertension Center; Director, Stanford Pre Renal Initiative; former Chair, Council on Kidney and Cardiovascular Disease, AHA

#ENDO2026 Welcomes Your Ideas | Our annual meeting will take place in Chicago, IL, June 13–16, and I’m inviting YOU to shape the program💡Submit your symposium proposal or session suggestion by Tuesday, September 2: bit.ly/4flCMjl #endocrinology @TheEndoSociety

ENDO 2026 Session Submissions

ENDO wouldn’t be possible without the insight and expertise of the Endocrine community. Your ideas are essential to building a dynamic, forward-thinking program that reflects the full breadth of our f...

bit.ly

Presented at the #ADASciSessions: Zimislecel is an allogeneic stem cell–derived islet-cell therapy. This phase 1–2 study supports the hypothesis that zimislecel can restore physiologic islet function and thus treat persons with type 1 diabetes. Full study results: nej.md/3ZGupbv

Stem Cell–Derived, Fully Differentiated Islets for Type 1 Diabetes | NEJM

Zimislecel is an allogeneic stem cell–derived islet-cell therapy. Data on the safety and efficacy of zimislecel in persons with type 1 diabetes are needed. We conducted a phase 1–2 study of zimisle...

nej.md

Atul Butte died yesterday. The world lost a giant. A big bear of a man. With a huge smile. With love for everyone. With energy that could power a room. I loved everything about Atul. I loved how he was always happy. I loved how excited he was about science and helping people.

Bild

Congratulations to all who advocated and thank you to all those who supported!! 🎉🎉🎉🎉🎉 @WHO.int @ISN.org #Guatamala @CharuMalik.bsky.social Ifeoma Ulasi Magda Machalska @UKKidney.org @kidneycareuk.org @KidneyResearch.org #kidneyhealthforall #WHA78

ISNkidneycare@theisn.org · last yr.

🌍 History made! For the first time, kidney care is on the global health agenda. #WHA78 adopted a landmark resolution recognizing kidney health in the fight against #NCDs. 👏 Thanks to Guatemala and the global kidney community for making this possible! #KidneyHealthMatters

In the Advance-HTN phase 2b trial of the aldosterone synthase inhibitor lorundrostat in participants with uncontrolled hypertension, lorundrostat was associated with greater reductions in blood pressure than placebo. Full trial results: nej.md/4ipbCIf #MedSky #CardioSky

A graph showing the least-squares mean changes from baseline (randomization) in the 24-hour average ambulatory systolic blood pressure at 12 weeks.

Aaand it’s official, we have a new antihypertensive class!!!! 🎉🍾🎊 I like this RCT design in particular because it was open to both uncontrolled not-yet-resistant AND resistant hypertensive patients, opening to door to prescribe it as an earlier line agent www.nejm.org/doi/full/10....

Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension | NEJM

Aldosterone dysregulation contributes to hypertension. Lorundrostat is an aldosterone synthase inhibitor, but data on its efficacy and safety in patients with hypertension are limited. In this mult...

nejm.org

The Women's Health Initiative is one of the most impactful studies in US history. It's been ongoing since the '90s, continually providing new insights, and NIH is cutting funding. Regional Centers are being closed. The Clinical Coordinating Center is now in limbo. For what? Utterly asinine... 🤬